Feature|Articles|May 22, 2026

Inside the FDA's Commissioner's National Priority Voucher Program: Promise, Pressure, and Operational Reality

The CNPV program has compressed drug review timelines to as little as one to two months for qualifying sponsors, but succeeding under that pressure requires a fundamental rethink of how development teams plan, communicate, and execute.

When the FDA launched the Commissioner's National Priority Voucher (CNPV) program in mid-2025, it represented one of the most aggressive regulatory timeline compressions in modern drug development.1